Entity
Biogen
Biogen is a biotechnology company that develops and sells therapies for neurological and neurodegenerative diseases, including Alzheimer's disease.
Why it’s in the news: It is in the news due to new data on its Alzheimer's drug and the development of its tau therapy.
Latest on Biogen
- STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and more
- STAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study shows
- STAT+: All eyes on data on Biogen’s tau therapy
- 13F: Thor Investment Management Oh Adv holds Biogen ($2M)
- 13F: Contravisory Investment Management holds Biogen ($10M)
Connections
7 entities linked to Biogen across the news graph.
Also connected to (7)
STAT+: Pharmalittle: We’re reading about a Biogen Alzheimer’s drug, skyrocketing 340B drug sales, and moreSTAT+: Biogen Alzheimer’s drug slowed decline at rates on par with approved therapies, study showsSTAT+: All eyes on data on Biogen’s tau therapyThor Investment Management Oh AdvContravisory Investment ManagementAllSTAT